CClinicalTrials.gg
Sign In
WithdrawnNCT03191383Updated Oct 15, 2018

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

A Phase 2 interventional study of RSV vaccine (GSK3003891A) formulation 1 and RSV vaccine (GSK3003891A) formulation 2 in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Withdrawn at 12 sites in 3 countries. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-15.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Why this study was withdrawn
Study was canceled due to instability of the PreF antigen during manufacturing. No safety concern has been identified in past or ongoing studies.
Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK RSV vaccine in pregnant women aged 18 to 40 years and infants born to the vaccinated women

02

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Maternal immunization
  • Immunogenicity
  • Vaccines
  • Safety
  • Reactogenicity
  • Respiratory Syncytial Virus
03

In context

Respiratory Syncytial Virus Infections

293 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 45 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.

Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written informed consent for study participation of the mother obtained from the mother or the mother and father, as applicable by local law, prior to performance of any study specific procedure.
  • Written informed consent for study participation of the infant obtained from the infant's mother and/or father, as applicable by local law, or legally acceptable representative [LAR] prior to performance of any study specific procedure.
  • Subjects between, and including, 18 and 40 years of age at the time of the first study visit.
  • Pregnant females > 24 weeks of gestation at the time of screening and at 28 0/7 to 33 6/7 weeks of gestation at the time of vaccination, as established by ultrasound examination and last menstrual period date.
  • Healthy pregnant females as established by medical history and clinical examination before entering into the study.
  • Pregnant females not at high risk for complications, as determined by the obstetrical risk assessment form.
  • No significant foetal findings observed during a second or third trimester ultrasound.
  • Subjects who are willing to provide cord blood.
  • Subjects who do not plan to give their child for adoption or place the child in care.

Inclusion Criteria infants:

  • Re-signed written informed consent for study participation of the infant obtained from the infant's mother and/or father, as applicable by local law, or LAR.

Exclusion Criteria:

  • Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before vaccination , or planned use during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before vaccination and ending at delivery with the exception of seasonal influenza vaccine and diphtheria, tetanus, pertussis/tetanus, diphtheria, pertussis [dTpa/Tdap] vaccine as part of standard of care which may be administered ≥ 15 days before or after study vaccination.
  • Chronic administration of systemic immunosuppressants or other immune-modifying drugs, as well as administration of long-acting immune-modifying drugs during the period starting 6 months prior to study vaccination, or planned administration up to delivery. Topical steroids are allowed. Inhaled steroids are allowed up to the limit of ≤500 µg/day for beclomethasone or fluticasone, or ≤ 800 µg/day for budesonide.
  • Administration of immunoglobulins (with the exception of prophylactic anti-Rh0D immune globulin) and/or any blood products during the period starting 3 months before study vaccination or planned administration during the study period.
  • Previous experimental vaccination against RSV.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Low lying placenta during the current pregnancy, unless there is documented sonographic evidence that the placenta has moved up prior to enrolment.
  • Any abnormal finding observed in nuchal translucency scan, serum testing and any other prenatal tests, if conducted.
  • Incompetent cervix or cerclage during the current pregnancy.
  • Having received medical treatment for suspected preterm delivery during the current pregnancy.
  • Prior preterm delivery or having ongoing intervention in current pregnancy to prevent preterm delivery.
  • Prior stillbirth or neonatal death, or ≥ 2 spontaneous abortions.
  • Personal history of major congenital anomalies or early onset of eclampsia/pre-eclampsia in previous pregnancy.
  • 1st degree relatives family history of major congenital anomalies and/ or hereditary immunodeficiency.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • Hemodynamically significant cardiac disorders.
  • Gestational diabetes as determined by glucose challenge/tolerance test conducted after 20 weeks of gestation or as per local recommendations of the country, requiring intervention other than diet for control. In countries where glucose challenge/tolerance testing is not routinely performed in all pregnant women, should the screening urinalysis test show presence of glucose in urine, a glucose challenge/tolerance test should be performed and results should be available prior to enrolment, in order to exclude gestational diabetes prior to subject receiving the study vaccine.
  • History of gestational diabetes in previous pregnancy(ies).
  • Hypertension during the current pregnancy as defined below or if any antihypertensive medication is being provided, or history of hypertension requiring antihypertensive medication:

Hypertension during current pregnancy is defined as:

  • a blood pressure systolic > 140 and/or diastolic 90 mmHg, documented in at least 2 separate measurements .

    • Current obstetric cholestasis or history of obstetric cholestasis.
    • Asthma and/or chronic obstructive pulmonary disease [COPD] if the subject is receiving treatment with chronic systemic glucocorticoids at any dose or inhaled glucocorticoids > 500 µg/day of beclomethasone or fluticasone, or > 800 µg/day of budesonide.
    • Significant neuro-psychiatric illness deemed likely to interfere with protocol compliance, safety reporting or receipt of pre-natal care, or requiring treatment with psychotropic drugs.
    • Diagnosed with Zika virus infection or suspected to have or have had Zika virus infection during the current pregnancy.
    • Known HIV infection, as assessed by local standard of care serologic tests conducted during the current pregnancy and prior to enrolment.
    • Known or suspected Hepatitis B virus [HBV] or Hepatitis C virus [HCV] infection.
    • Known infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Rubella, cytomegalovirus [CMV] or primary Herpes Simplex.
    • Known foetal anomalies in the current pregnancy.
    • Any clinically significant haematological and/or biochemical laboratory abnormality.

  • Subjects with haematological/ biochemical values out of normal range which are expected to be temporary may be re-screened at a later date within the allowed time interval.

    • Acute disease and/or fever within 3 days prior to enrolment .
  • Fever is defined as temperature ≥ 37.5°C/99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C/100.4°F for rectal route.
  • Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.

  • For subjects with acute disease and/ or fever at the time of enrolment, Visit 1 may be scheduled at a later date within the allowed time interval and gestational age.

    • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
    • Hypersensitivity to latex.
    • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
    • History of drug or alcohol abuse within the past 2 years.
    • Any condition which, in the investigator's opinion, would increase the risks of study participation to the unborn infant.
    • Planned move to a location that will prohibit participating in the trial until study end.

Exclusion Criteria infants:

  • Any condition which, in the investigator's opinion, would increase the risks of study participation to the infant.
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    GSK3003891A vaccine formulation 1 mother Group

    Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.

    Biological: RSV vaccine (GSK3003891A) formulation 1

  • Experimental
    GSK3003891A vaccine formulation 2 mother Group

    Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.

    Biological: RSV vaccine (GSK3003891A) formulation 2

  • Experimental
    GSK3003891A vaccine formulation 3 mother Group

    Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.

    Biological: RSV vaccine (GSK3003891A) formulation 3

  • Placebo comparator
    Control group

    Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.

    Drug: Placebo (Formulation buffer S9b)

  • No intervention
    GSK3003891A vaccine formulation 1 infant Group

    Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine

  • No intervention
    GSK3003891A vaccine formulation 2 infant Group

    Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine

  • No intervention
    GSK3003891A vaccine formulation 3 infant Group

    Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine

  • No intervention
    Control infant Group

    Infants born to mothers who received a single placebo injection

Interventions

  • BiologicalRSV vaccine (GSK3003891A) formulation 1

    Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

  • BiologicalRSV vaccine (GSK3003891A) formulation 2

    Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

  • BiologicalRSV vaccine (GSK3003891A) formulation 3

    Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

  • DrugPlacebo (Formulation buffer S9b)

    Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

06

What researchers measure

Primary outcomes

  1. Number of subjects with solicited local adverse events (AEs)

    Assessed solicited local symptoms are pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevents normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: During a 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days)

  2. Number of subjects with solicited general AEs

    Assessed solicited general symptoms are fatigue, fever \[defined as oral/axillary/tympanic route temperature equal to or above 37.5 degrees Celsius (°C) or ≥ 38 °C for rectal route\], gastrointestinal symptoms \[nausea, vomiting, diarrhoea and/or abdominal pain\] and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevents normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination

    Time frame: During the 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days)

  3. Number of subjects with unsolicited AEs

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevents normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: During a 30-day follow-up period after vaccination (i.e. the day of vaccination and 29 subsequent days)

  4. Number of subjects with haematological abnormalities

    Haematological laboratory abnormalities include haemoglobin level, white blood cell count \[WBC\], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.

    Time frame: At Day 0

  5. Number of subjects with haematological abnormalities

    Haematological laboratory abnormalities include haemoglobin level, white blood cell count \[WBC\], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.

    Time frame: At Day 7

  6. Number of subjects with biochemical abnormalities

    Biochemical laboratory abnormalities include alanine amino-transferase \[ALT\], aspartate amino-transferase \[AST\], creatinine and blood urea nitrogen.

    Time frame: At Day 0

  7. Number of subjects with biochemical abnormalities

    Biochemical laboratory abnormalities include alanine amino-transferase \[ALT\], aspartate amino-transferase \[AST\], creatinine and blood urea nitrogen.

    Time frame: At Day 7

  8. Number of subjects with any serious adverse events (SAEs)

    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From study start (Day 0) up to 6 months after delivery

  9. Number of infant subjects with any SAEs

    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From birth up to 6 months after birth

  10. Number of subjects with pregnancy outcomes

    Pregnancy outcomes include live birth with no congenital anomalies, live birth with congenital anomalies, foetal death/still birth with no congenital anomalies, foetal death/still birth with congenital anomalies, elective/therapeutic termination with no congenital anomalies and elective/therapeutic termination with congenital anomalies.

    Time frame: From study start (Day 0) up to delivery

  11. Number of subjects with pregnancy-related AEs of specific interest

    Pregnancy-related adverse events of specific interest include: gestational diabetes, gestational liver disease (including obstetric cholestasis and acute fatty liver of pregnancy), chorioamnionitis, labour protraction and arrest disorders, maternal sepsis, pregnancy-related hypertension, preterm premature rupture of membranes, premature labour, intrauterine growth restriction/poor foetal growth, pre-eclampsia and eclampsia, vaginal or intrauterine haemorrhage, medical conditions necessitating early delivery (induced labour or urgent C-section) (placenta abruption, uterine infection, oligohydramnios, etc), maternal death.

    Time frame: From study start (Day 0) up to delivery

  12. Number of infant subjects with AEs of specific interest

    Infant-related AEs of specific interest include preterm birth, neonatal death, low birth weight and/or small for gestational age, neonatal sepsis, foetal/perinatal distress or asphyxia, failure to thrive/growth deficiency, congenital anomalies and neurodevelopmental delay.

    Time frame: From birth up to 6 months after birth

Secondary outcomes

  1. Number of infant subjects with SAEs

    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From birth and up to study end (Year 2)

  2. Number of infant subjects with AEs potentially related to maternal vaccination

    Related infant AEs = AEs occurring in the infant assessed by the investigator as potentially related to the vaccination of the mother.

    Time frame: From birth up to study end (Year 2)

  3. Number of infant subjects with neuro-developmental delays

    Infant subjects with Ages and Stages Questionnaires version 3 (ASQ-3) scores in the grey and black zones for any of the 5 developmental areas or domains (communication, gross motor skills, fine motor skills, problem solving and personal-social) : Grey zone (i.e. Monitoring zone) score means that the child's score falls ≥ 1 but \<2 standard deviations below the mean score in any developmental area. Black zone (i.e. Referral zone) score means that the child's score falls below the cut-off (i.e. 2 standard deviations below the mean score) in any developmental area. Infant subjects scoring in the black zone in any of the 5 domains of the ASQ-3 will be referred for formal neurological evaluation

    Time frame: At Year 1 and Year 2

  4. Number of infant subjects referred for formal neurological evaluation

    Neuro-developmental formal evaluation will be performed, for infants with ASQ3 black zone scores, using the Bayley Scale for Infant Development, Version III (BSID-III) or an equivalent.

    Time frame: At Year 1 and Year 2

  5. Number of infant subjects with confirmed developmental delay

    Infants confirmed as having neuro-developmental delay following formal evaluation using the Bayley Scale for Infant Development, Version III (BSID-III) or an equivalent.

    Time frame: At Year 1 and Year 2

  6. Neutralizing antibody titres against RSV-A, for all vaccinated mothers

    Titres will be expressed as geometric mean titres (GMTs)

    Time frame: At pre-vaccination (Day 0), Day 30 and Day 60 post vaccination and at delivery

  7. Neutralizing antibody titres against RSV-B, for all vaccinated mothers

    Titres will be expressed as geometric mean titres (GMTs)

    Time frame: At pre-vaccination (Day 0), Day 30 and Day 60 post vaccination and at delivery

  8. Palivizumab competing antibody (PCA) concentrations, for all vaccinated mothers.

    Concentrations will be expressed as geometric mean concentrations (GMCs)

    Time frame: At pre-vaccination (Day 0), Day 30 and Day 60 post-vaccination and at delivery

  9. Neutralizing antibody titres against RSV-A, for all infants born to vaccinated mothers

    Titres will be expressed as geometric mean titres (GMTs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.

    Time frame: At birth, at Month 3 and at Month 6

  10. Neutralizing antibody titres against RSV-B, for all infants born to vaccinated mothers

    Titres will be expressed as geometric mean titres (GMTs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.

    Time frame: At birth, at Month 3 and at Month 6

  11. PCA concentrations, for all infants born to vaccinated mothers

    Concentrations will be expressed as geometric mean concentrations (GMCs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.

    Time frame: At birth, at Month 3 and at Month 6

  12. Number of infant subjects with lower respiratory tract infection (LRTI), severe LRTI and respiratory tract infection (RTI) with parental concern (according to the case definitions) associated with a respiratory syncytial virus (RSV) infection

    Occurrence of RSV-LRTI, severe RSV-LRTI, RSV-RTI with parental concern

    Time frame: From birth up to study end (Year 2)

  13. Number of subjects (vaccinated mothers) with medically-attended (MA) RTI associated with an RSV infection

    Occurrence of RSV associated MA-RTI. A MA-RTI is defined as a visit of the mother to a health care professional for any respiratory symptom, including cough, sputum production and difficulty breathing

    Time frame: From Day 0 up to Month 6 post delivery

07

Study locations

12 sites
  • GSK Investigational Site
    Newton, Kansas 67114, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Ellensburg, Washington 98926, United States
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Seinajoki, 60100, Finland
  • GSK Investigational Site
    Aravaca, 28023, Spain
  • GSK Investigational Site
    Burgos, 09006, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Majadahonda (Madrid), 28222, Spain
  • GSK Investigational Site
    Santiago de Compostela, 15706, Spain
  • GSK Investigational Site
    Santiago, 15705, Spain
  • GSK Investigational Site
    Sevilla, 41014, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through https://www.clinicalstudydatarequest.com/ following the timelines and process described on this site.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03191383
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 19, 2017
Start date
Jul 11, 2017
Primary completion
Jul 14, 2017
Completion
Jul 14, 2017
Last update
Oct 15, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Respiratory Syncytial Virus Infections→

Other studies from this sponsor

GlaxoSmithKline

Start the discussion